The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions - PubMed (original) (raw)

Review

The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions

Michael A Nauck et al. Lancet Diabetes Endocrinol. 2016 Jun.

Abstract

The incretin effect describes the phenomenon whereby oral glucose elicits higher insulin secretory responses than does intravenous glucose, despite inducing similar levels of glycaemia, in healthy individuals. This effect, which is uniformly defective in patients with type 2 diabetes, is mediated by the gut-derived incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). The importance of the incretin effect for the maintenance of glucose homoeostasis is clearly established, and incretin-based therapies are among the most promising new therapies for type 2 diabetes. However, despite the effectiveness of these therapies in many patients, the idea that they restore the incretin effect is a common misconception. In type 2 diabetes, the endocrine pancreas remains responsive to GLP-1 but is no longer responsive to GIP, which is the most likely reason for a reduced or absent incretin effect. Incretin-based drugs, including GLP-1 receptor agonists and dipeptidyl peptidase 4 (DPP-4) inhibitors, stimulate GLP-1 receptors and thus augment insulin secretion in response to both oral and intravenous glucose stimulation, thereby abolishing any potential difference in the responses to these stimuli. These drugs therefore do not restore the defective incretin effect in patients. By contrast, some bariatric surgical procedures enhance GLP-1 responses and also restore the incretin effect in obese individuals with type 2 diabetes. Thus, not all biological actions elicited by the stimulation of GLP-1 receptors lead to quantitative changes to the incretin effect.

PubMed Disclaimer

Cited by

Cyclic Adenosine Monophosphate in Cardiac and Sympathoadrenal GLP-1 Receptor Signaling: Focus on Anti-Inflammatory Effects.
Lymperopoulos A, Borges JI, Stoicovy RA. Lymperopoulos A, et al. Pharmaceutics. 2024 May 22;16(6):693. doi: 10.3390/pharmaceutics16060693. Pharmaceutics. 2024. PMID: 38931817 Free PMC article. Review.
Lixisenatide for Type 2 Diabetes Mellitus Patients Inadequately Controlled on Oral Antidiabetic Drugs: A Mixed-Treatment Comparison Meta-analysis and Cost-Utility Analysis.
Men P, Qu S, Song Z, Liu Y, Li C, Zhai S. Men P, et al. Diabetes Ther. 2020 Aug;11(8):1745-1755. doi: 10.1007/s13300-020-00857-3. Epub 2020 Jun 19. Diabetes Ther. 2020. PMID: 32562244 Free PMC article.
Association between Parkinson's Disease and Diabetes Mellitus: From Epidemiology, Pathophysiology and Prevention to Treatment.
Yu H, Sun T, He X, Wang Z, Zhao K, An J, Wen L, Li JY, Li W, Feng J. Yu H, et al. Aging Dis. 2022 Dec 1;13(6):1591-1605. doi: 10.14336/AD.2022.0325. eCollection 2022 Dec 1. Aging Dis. 2022. PMID: 36465171 Free PMC article.
The role of incretins in gestational diabetes: a case-control study on the impact of obesity.
Yurtcu E, Keyif B, Yilmaz G, Erkilinc S, Akkaya H, Ozgu-Erdinc AS. Yurtcu E, et al. Diabetol Metab Syndr. 2024 Oct 18;16(1):248. doi: 10.1186/s13098-024-01483-w. Diabetol Metab Syndr. 2024. PMID: 39420427 Free PMC article.
Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes.
Bahne E, Sun EWL, Young RL, Hansen M, Sonne DP, Hansen JS, Rohde U, Liou AP, Jackson ML, de Fontgalland D, Rabbitt P, Hollington P, Sposato L, Due S, Wattchow DA, Rehfeld JF, Holst JJ, Keating DJ, Vilsbøll T, Knop FK. Bahne E, et al. JCI Insight. 2018 Dec 6;3(23):e93936. doi: 10.1172/jci.insight.93936. JCI Insight. 2018. PMID: 30518693 Free PMC article. Clinical Trial.

The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions - PubMed (original) (raw)